Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - OPIANT PHARMACEUTICALS, INC.v460646_ex99-1.htm






Washington, D.C. 20549


Form 8-K


Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  February 28, 2017



(Exact name of registrant as specified in its charter)


Nevada   000-55330   46-4744124

(State or other jurisdiction

of incorporation)


(Commission File Number)


(IRS Employer Identification No.)


401 Wilshire Blvd., 12th Floor

Santa Monica, CA




(Address of Principal Executive Offices)

  (Zip Code)


(424) 252-4756

Registrant’s telephone number, including area code



(Former name or former address if changed since last report,)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01Other Events.


On February 28, 2017, Opiant Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company has received supportive feedback from the U.S. Food and Drug Administration on a proposed development plan for OPNT002, an intranasally-dosed opioid antagonist, for the treatment of Alcohol Use Disorder.


The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.


Item 9.01Financial Statements and Exhibits.




Exhibit No.Description


99.1Opiant Pharmaceuticals, Inc. Press Release, dated February 28, 2017.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


      Opiant Pharmaceuticals, Inc.
Date: February 28, 2017 By:    /s/ Dr. Roger Crystal
      Name: Dr. Roger Crystal
      Title: President and Chief Executive Officer